The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis
- PMID: 1690915
- DOI: 10.1111/j.1365-3083.1990.tb02772.x
The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis
Abstract
The influence of FK-506 and ciclosporin (CsA), either alone or in combination, on PHA- and alloantigen-induced human blood lymphocyte transformation was investigated. The concentrations of FK-506 and CsA required to cause 50% inhibition of mitogen-induced thymidine incorporation were 1.0 and 200 ng/ml respectively. Evidence of synergistic inhibition of DNA synthesis was obtained when doses of each drug below these concentrations were combined (FK-506, less than or equal to 0.5 ng/ml; CsA less than or equal to 50 ng/ml). In contrast, FK-506 and CsA failed to inhibit PHA-induced increases in cell size and granularity determined by flow cytometric analysis at 1 and 3 days of culture. Moreover, no significant changes in the expression of the interleukin 2 receptor (IL-2R; CD25), transferrin receptor (TR; CD71) or HLA-DR were observed in terms of percentage positive lymphocytes or mean cell surface membrane fluorescence intensity. In primary mixed lymphocyte cultures, 50% inhibition of thymidine incorporation was obtained with FK-506 and CsA concentrations of approximately 0.25 and 25 ng/ml respectively. Evidence of synergy was obtained when lower doses of each drug were combined (FK-506, less than or equal to 0.1 ng/ml; CsA less than or equal to 2 ng/ml). On their own, these concentrations of CsA were ineffective. In contrast to corresponding PHA-stimulated cells, FK-506-treated alloactivated lymphocytes exhibited reductions in IL-2R, TR and HLA-DR antigen expression, which in the cases of IL-2R and TR were further reduced by combination of FK-506 with low-concentration CsA. These data provide further evidence of the potential of combined low-dosage FK-506 and CsA for the control of human T-cell activation and proliferation in response to allostimulation.
Similar articles
-
Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.Transpl Immunol. 1993;1(2):146-50. doi: 10.1016/0966-3274(93)90009-w. Transpl Immunol. 1993. PMID: 7521738 Free PMC article.
-
Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis.Transplant Proc. 1990 Aug;22(4):1645-6. Transplant Proc. 1990. PMID: 1697113 No abstract available.
-
Antigen presentation and HLA-DR expression by FK-506-treated human monocytes.Immunology. 1990 Dec;71(4):551-5. Immunology. 1990. PMID: 1703987 Free PMC article.
-
Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.J Immunol. 1990 Jan 1;144(1):251-8. J Immunol. 1990. PMID: 1688572
-
The immunosuppressive macrolides FK-506 and rapamycin.Immunol Lett. 1991 Jul;29(1-2):105-11. doi: 10.1016/0165-2478(91)90209-s. Immunol Lett. 1991. PMID: 1717376 Review.
Cited by
-
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.Drugs. 1993 Oct;46(4):746-94. doi: 10.2165/00003495-199346040-00009. Drugs. 1993. PMID: 7506654 Review.
-
Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.Transpl Immunol. 1993;1(2):146-50. doi: 10.1016/0966-3274(93)90009-w. Transpl Immunol. 1993. PMID: 7521738 Free PMC article.
-
Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.Clin Exp Immunol. 1990 Dec;82(3):462-8. doi: 10.1111/j.1365-2249.1990.tb05472.x. Clin Exp Immunol. 1990. PMID: 1702375 Free PMC article.
-
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.Mult Scler Int. 2012;2012:935921. doi: 10.1155/2012/935921. Epub 2012 Aug 15. Mult Scler Int. 2012. PMID: 22966460 Free PMC article.
-
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis.Immunology. 1990 Jul;70(3):398-404. Immunology. 1990. PMID: 1696242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials